Actuate Therapeutics Announces Pricing of IPO By Investing.com

CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the Company)a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers, today announced the pricing of its initial public offering of 2,800,000 shares of its common stock at a price of $8.00 per share to the public for total gross proceeds to the Company of $22,400,000, before deducting underwriting discounts and offering expenses (the Offering).

In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 420,000 shares representing 15% of the shares sold in this offering, solely to cover potential over-allotments, net of the underwriting discount. All shares are being offered by the Company.

The shares are expected to begin trading on the Nasdaq Global Market tomorrow, August 13, 2024, under the symbol “ACTU.” The offering is expected to close on August 14, 2024, subject to the satisfaction of customary closing conditions.

Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager.

A registration statement on Form S-1 (the registration statement) relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 12, 2024. The offering is being made only by means of a prospectus, which forms a part of the effective registration statement. A copy of the final prospectus relating to the offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or by email at [email protected] or by telephone at (929) 833-1246. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional anticancer drugs such as chemotherapy, including multiple DDR pathways. Elraglusib is designed to mediate antitumor immunity through inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For more information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements about us and our industry. Forward-looking statements involve substantial risks and uncertainties, including those described under the heading Risk Factors in Actuate’s registration statement. All statements, other than statements of current facts or conditions or historical facts, contained in this press release, including statements regarding the anticipated commencement of trading of Actuate’s common stock on The Nasdaq Global Market and the closing date of the Offering, are forward-looking statements. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. The words anticipate, believe, continue, could, estimate, expect, intend, may, could, ongoing, plan, potential, predict, project, should, target, will, would, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading Risk Factors in this prospectus or any related free-draft prospectus.

You should assume that the information in this press release is accurate as of the date of its release only. Because the risk factors discussed above could cause actual results to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on these forward-looking statements. Furthermore, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and we cannot predict what factors will emerge. Furthermore, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in the forward-looking statements. Except as required by law, we undertake no obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact details

Investors:
Mike Moyer
LifeSci Advisors
+1 (617) 308-4306
[email protected]

Source: Actuate Therapeutics